,english_text,turkish_text,translation_is_valid
0,"For a long time non communicable diseases (NCDs) were discussed as burden of the developed world. Recent alarming data show a reverse trend and a dramatic increase of NCDs in the developing world, in particular in highly populated transition countries. This is true for the main mortality triggering diseases such as CVD, cancer or diabetes. Almost 4 out of 5 NCD based deaths happen in low- and middle income countries. This development is multi-factorial and is based on some main trends such as globalization, supermarket growth, rapid urbanization and increasingly sedentary lifestyles. The latter leads to overweight or obesity, which again promotes NCDs similar as high blood pressure, high cholesterol and elevated blood glucose. A high quality diet including functional food or functional ingredients, accompanied by physical activity and a non-smoking policy, is one of the most promising factors in primary and secondary prevention of NCDs. Copyright © 2011 Elsevier Inc. All rights reserved.","Uzun bir süredir, bulaşıcı olmayan hastalıklar (NCD'ler), gelişmiş dünyanın yükü olarak tartışılıyordu. Son zamanlarda endişe verici veriler, özellikle yüksek nüfuslu geçiş ülkelerindeki NCD'lerin dramatik bir artışını gösteren ters bir eğilim ortaya koyuyor. Bu, kalp damar hastalıkları, kanser veya diyabet gibi ana ölümcül hastalıklar için de geçerlidir. NCD'lere dayalı neredeyse 4 ölümden 5'i düşük ve orta gelirli ülkelerde gerçekleşiyor. Bu gelişme çok yönlüdür ve küreselleşme, süpermarketlerin büyümesi, hızlı kentleşme ve giderek daha fazla oturaklı yaşam tarzları gibi ana eğilimler üzerine kuruludur. Sonuncusu, aşırı kilolu veya obeziteye yol açar, bu da yüksek tansiyon, yüksek kolesterol ve yükselmiş kan şekeri gibi NCD'leri teşvik eder. Yüksek kaliteli bir diyet, işlevsel gıda veya işlevsel bileşenleri içerir, fiziksel aktivite ve sigara içmeme politikası ile birlikte, NCD'lerin birincil ve ikincil önlenmesinde en umut verici faktörlerden biridir. Telif Hakkı © 2011 Elsevier B.V. Tüm hakları saklıdır.",True
1,"Sulforaphane (SFR), an isothiocyanate from cruciferous vegetables, possesses growth-inhibiting and apoptosis-inducing activities in cancer cell lines. Recently, SFR has been shown to promote the mitochondrial formation of reactive oxygen species (ROS) in human cancer cell lines. The present study was undertaken to see whether SFR-derived ROS might cause DNA damage in cultured human cells, namely T limphoblastoid Jurkat and human umbilical vein endothelial cells (HUVEC). 1-3 h treatments with 10-30 microM SFR elicited intracellular ROS formation (as assayed with dihydrorhodamine, DHR, oxidation) as well as DNA breakage (as assessed with fast halo assay, FHA). These effects lacked cell-type specificity, since could be observed in both Jurkat and HUVEC. Differential-pH FHA analysis of damaged DNA showed that SFR causes frank DNA single strand breaks (SSBs); no DNA double strand breaks (DSBs) were found within the considered treatment times (up to 3 h). SFR-derived ROS were formed at the mitochondrial respiratory chain (MRC) level: indeed rotenone or myxothiazol (MRC Complex I and III inhibitors, respectively) abrogated ROS formation. Furthermore ROS were not formed in Jurkat cells pharmacologically depleted of respiring mitochondria (MRC-/Jurkat). Formation of ROS was causally linked to the induction of SSBs: indeed all the experimental conditions capable of preventing ROS formation also prevented the damage of nuclear DNA from SFR-intoxicated cells. As to the toxicological relevance of SSBs, we found that their prevention slightly but significantly attenuated SFR cytotoxicity, suggesting that high-dose SFR toxicity is the result of a complex series of events among which GSH depletion seems to play a pivotal role. In conclusion, the present study identifies a novel mechanism contributing to SFR toxicity which - since DNA damage is a prominent mechanism underlying the cytotoxic activity of established antineoplastic agents - might help to exploit the therapeutic value of SFR in anticancer drug protocols. Copyright 2010 Elsevier B.V. All rights reserved.","Sülforafan (SFR), kükürtlü sebzelerden elde edilen bir izosiyanat, kanser hücre hatlarında büyüme baskılayıcı ve apoptoz indükleyici etkinliklere sahiptir. Son zamanlarda, SFR'nin insan kanser hücre hatlarında mitokondride reaktif oksijen türlerinin (ROS) oluşumunu teşvik ettiği gösterilmiştir. Bu çalışmanın amacı, SFR'den kaynaklanan ROS'un kültürlenmiş insan hücrelerinde, özellikle T limfoblastoid Jurkat ve insan at nalı damar endoteli hücreleri (HUVEC) gibi hücrelerde DNA hasarına neden olup olmadığını incelemektir. 1-3 saatlik 10-30 mikroM SFR tedavileri, dihidroehmin (DHR) oksidasyonu ile ölçülen hücre içi ROS oluşumunu ve hızlı halo testi (FHA) ile değerlendirilen DNA kırığını tetikledi. Bu etkiler hücre türüne özgü değildi, çünkü hem Jurkat hem de HUVEC hücrelerinde gözlemlenebildi. Farklı pH'da FHA analizi, SFR'den kaynaklanan DNA'nın açık DNA tek iplikli kırıkları (SSB'ler) neden olduğunu gösterdi; herhangi bir DNA çift iplikli kırığı (DSB'ler) 3 saatlik tedavi süreleri içinde (en fazla 3 saat) bulunmadı. SFR'den kaynaklanan ROS, mitokondri solunum zinciri (MRC) düzeyinde oluştu: gerçekten de rotenon veya myxothiazol (MRC Kompleks I ve III inhibitörleri, sırasıyla) ROS oluşumunu engelledi. Ayrıca, Jurkat hücrelerinde mitokondri solunumunu farmakolojik olarak azaltan (MRC-/Jurkat) ROS, Jurkat hücrelerinde de oluşmadı. ROS oluşumu, SSB'lerin indüklenmesiyle kausal olarak bağlantılıydı: gerçekten de ROS oluşumunu önleyen tüm deneysel koşullar, SFR ile zehirlenmiş hücrelerin nükleer DNA'sının hasar görmesini de önledi. SSB'lerin toksikolojik önemi açısından, SSB'lerin önlenmesinin, SFR'nin yüksek doz toksisitesini hafif ama anlamlı bir şekilde azalttığını bulduk, bu da GSH'nin tükenmesinin, bilinen antineoplastik ajanların sitotoksik etkinliğinin altında yatan önemli bir mekanizma olduğu göz önüne alındığında, SFR'nin antikanser ilaç protokollerinde terapötik değerini kullanmaya yardımcı olabileceğini",True
2,"OBJECTIVES: Patients with chronic constipation due to food hypersensitivity (FH) had an elevated anal sphincter resting pressure. No studies have investigated a possible role of FH in anal fissures (AFs). We aimed to evaluate (1) the effectiveness of diet in curing AFs and to evaluate (2) the clinical effects of a double-blind placebo-controlled (DBPC) challenge, using cow's milk protein or wheat. METHODS: One hundred and sixty-one patients with AFs were randomized to receive a ""true-elimination diet"" or a ""sham-elimination diet"" for 8 weeks; both groups also received topical nifedipine and lidocaine. Sixty patients who were cured with the ""true-elimination diet"" underwent DBPC challenge in which cow's milk and wheat were used. RESULTS: At the end of the study, 69% of the ""true-diet group"" and 45% of the ""sham-diet group"" showed complete healing of AFs (P<0.0002). Thirteen of the 60 patients had AF recurrence during the 2-week cow's milk DBPC challenge and 7 patients had AF recurrence on wheat challenge. At the end of the challenge, anal sphincter resting pressure significantly increased in the patients who showed AF reappearance (P<0.0001), compared with the baseline values. The patients who reacted to the challenges had a significantly higher number of eosinophils in the lamina propria and intraepithelial lymphocytes than those who did not react to the challenges. CONCLUSIONS: An oligo-antigenic diet combined with medical treatment improved the rate of chronic AF healing. In more than 20% of the patients receiving medical and dietary treatment, AFs recurred on DBPC food challenge.","
## Amaçlar:
Yiyecek hipersensitivitesine (FH) bağlı kronik kabızlık yaşayan hastalarda anal sfinkter istirahat basıncı yükselmişti. Anal çatlaklar (AF) üzerinde olası bir FH rolünü araştıran hiçbir çalışma yoktu. AF'lerin iyileşmesinde diyetin etkinliğini değerlendirmeyi ve (2) bir çift kör plasebo kontrollü (DBPC) testin klinik etkilerini değerlendirmeyi amaçladık.

## Yöntemler:
AF'leri olan 161 hasta, 8 hafta boyunca ""gerçek elimine diyet"" veya ""sahte elimine diyet""e rastgele atandı; her iki grup da topikal nifedipin ve lidokain aldı. ""Gerçek elimine diyet"" ile iyileşen 60 hasta, inek sütü ve buğday içeren DBPC testine tabi tutuldu.

## Sonuçlar:
Çalışmanın sonunda, ""gerçek diyet grubu""nun %69'u ve ""sahte diyet grubu""nun %45'i AF'lerinde tam iyileşme gösterdi (P<0.0002). 60 hastadan 13'ü inek sütü DBPC testinde ve 7 hasta buğday testinde AF tekrarı yaşadı. Testin sonunda, AF'leri tekrar gösteren hastalarda anal sfinkter istirahat basıncı, temel değerlere kıyasla anlamlı şekilde arttı (P<0.0001). Testlere tepki veren hastalar, tepki vermeyenlere kıyasla lamina propria'da eozinofil ve intraepitelyal lenfosit sayısında anlamlı bir artış gösterdi.

## Sonuç:
Oligo-antijenik diyet ve tıbbi tedavi kombinasyonu kronik AF iyileşme oranını artırdı. Tıbbi ve diyet tedavisi alan hastaların %20'den fazlası, DBPC gıda testinde AF tekrarı yaşadı.",True
3,"Snacking is an uncontrolled eating behavior, predisposing weight gain and obesity. It primarily affects the female population and is frequently associated with stress. We hypothesized that oral supplementation with Satiereal (Inoreal Ltd, Plerin, France), a novel extract of saffron stigma, may reduce snacking and enhance satiety through its suggested mood-improving effect, and thus contribute to weight loss. Healthy, mildly overweight women (N = 60) participated in this randomized, placebo-controlled, double-blind study that evaluated the efficacy of Satiereal supplementation on body weight changes over an 8-week period. Snacking frequency, the main secondary variable, was assessed by daily self-recording of episodes by the subjects in a nutrition diary. Twice a day, enrolled subjects consumed 1 capsule of Satiereal (176.5 mg extract per day (n = 31) or a matching placebo (n = 29). Caloric intake was left unrestricted during the study. At baseline, both groups were homogeneous for age, body weight, and snacking frequency. Satiereal caused a significantly greater body weight reduction than placebo after 8 weeks (P < .01). The mean snacking frequency was significantly decreased in the Satiereal group as compared with the placebo group (P < .05). Other anthropometric dimensions and vital signs remained almost unchanged in both groups. No subject withdrawal attributable to a product effect was reported throughout the trial, suggesting a good tolerability to Satiereal. Our results indicate that Satiereal consumption produces a reduction of snacking and creates a satiating effect that could contribute to body weight loss. The combination of an adequate diet with Satiereal supplementation might help subjects engaged in a weight loss program in achieving their objective. Copyright 2010 Elsevier Inc. All rights reserved.","Atıştırmalık, kontrolsüz bir yemek davranışıdır, kilo alımı ve obeziteye yatkınlığı artırır. Öncelikle kadın nüfusa etki eder ve stresle sık sık ilişkilendirilir. Hipotezimiz, Satiereal (Inoreal Ltd, Plerin, Fransa) adlı yenilikçi safran damarı ekstraktının ağız yoluyla takviyesi, ruh halini iyileştiren etkisinin önerildiği için atıştırmalığı azaltabilir ve doyuruculuğu artırabilir ve bu da kilo vermeye katkıda bulunabilir. Bu çalışmada, sağlıklı, hafif aşırı kilolu kadınlar (N = 60) yer aldı. 8 haftalık bir süre boyunca vücut ağırlığındaki değişiklikleri değerlendirmek için, Satiereal takviyesinin etkinliğini inceleyen, rastgele, plasebo kontrollü, çift kör bir çalışma yapıldı. Ana ikincil değişken olan atıştırma sıklığı, katılımcıların günlük olarak beslenme günlüğüne kaydettiği epizodlar tarafından değerlendirildi. Günlük olarak, kayıtlı katılımcılar 1 Satiereal kapsülü (günlük 176.5 mg ekstrakt (n = 31) veya eşdeğer plasebo (n = 29) tükettiler. Çalışma süresince kalori alımı kısıtlanmadı. Temel seviyede, her iki grup da yaş, vücut ağırlığı ve atıştırma sıklığı açısından homojen idi. Satiereal, 8 hafta sonra plaseboya kıyasla anlamlı bir vücut ağırlığı azalmasına neden oldu (P < .01). Satiereal grubunda plaseboya kıyasla atıştırma sıklığı anlamlı şekilde azaldı (P < .05). Diğer antropometrik boyutlar ve hayati işaretler her iki grupta neredeyse değişmedi. Çalışmanın tamamında, Satiereal'in bir ürün etkisi nedeniyle bir katılımcının çekilmesi bildirilmedi, bu da Satiereal'in iyi tolere edildiğini gösteriyor. Sonuçlarımız, Satiereal tüketiminin atıştırmalığı azalttığını ve doyurucu bir etki yarattığını gösteriyor, bu da vücut ağırlığı kaybına katkıda bulunabilir. Uygun bir diyetin Satiereal takviyesi ile birleştirilmesi, kilo vermeye çalışan katılımcıların hedeflerine ulaşmasına yardımcı olabilir. 2010 Elsevier B.V. Tüm hakları saklıdır.",True
4,"BACKGROUND: The role of zoonotic biological agents in human cancer occurrence has been little studied. Humans are commonly exposed to viruses that naturally infect and cause cancer in food animals such as poultry that constitute part of the biological environment. It is not known if these viruses cause cancer in humans. OBJECTIVE: To study cancer mortality in the largest cohort to date, of 20,132 workers in poultry slaughtering and processing plants, a group with the highest human exposures to these viruses. METHODS: Mortality in poultry workers was compared with that in the US general population through the estimation of standardized mortality ratios. RESULTS: Significantly increased risks were observed in the cohort as a whole or in subgroups, for several cancer sites, viz: cancers of the buccal cavity and pharynx; pancreas; trachea/bronchus/lung; brain; cervix; lymphoid leukemia; monocytic leukemia; and tumors of the hemopoietic and lymphatic systems. Elevated SMRs that were not statistically significant were observed for cancers of the liver, nasopharynx, myelofibrosis, and myeloma. New sites observed to be significantly in excess in this study were cancers of the cervix and penis. CONCLUSION: This large study provides evidence that a human group with high exposure to poultry oncogenic viruses has increased risk of dying from several cancers. Other occupational carcinogenic exposures could be of importance in explaining some of the findings, such as fumes from wrapping machines. These findings may have implications for public health amongst persons in the general population who may also be exposed to these viruses. What is needed now are epidemiologic studies that can demonstrate whether the excess of specific cancers can be attributed to specific occupational exposures while adequately controlling for other potential occupational and non-occupational carcinogenic exposures. Copyright 2010 Elsevier Inc. All rights reserved.","ARKA PLAN: İnsanlarda kanser oluşmasında zoonotik biyolojik ajanların rolü çok az araştırılmıştır. İnsanlar, doğal olarak enfekte olup gıda hayvanlarında kansere neden olan virüslere yaygın olarak maruz kalırlar, örneğin tavuklar, bu biyolojik ortamın bir parçasıdır. Bu virüslerin insanlarda kansere neden olup olmadığı bilinmemektedir.

HEDEF: En büyük koçta şimdiye kadar incelenen 20.132 tavuk işleme ve kesimi tesislerinde çalışanlar, bu virüslere en yüksek insan maruz kalımına sahip bir grup üzerinde kanser ölümlerini incelemek.

YÖNTEMLER: Tavuk işçilerinin ölüm oranı, ABD genel nüfusu ile karşılaştırmak için standartlaştırılmış ölüm oranları (SMR) ile tahmin edildi.

SONUÇLAR: Tüm grup veya alt gruplar için birkaç kanser türü için önemli artmış riskler gözlemlendi: ağız boşluğu ve farenks kanseri; pankreas; trakea/bronş/akciğer; beyin; serviks; lösemi; monositik lösemi; ve hemopoitik ve lenfatik sistem tümörleri. Hepatit, nasofarenks, mielofibroz ve mieloma için yükseltilmiş ancak istatistiksel olarak anlamlı olmayan SMR'lar gözlemlendi. Bu çalışmada önemli ölçüde fazla görülen yeni kanser türleri serviks ve penis kanseriydi.

SONUÇ: Bu büyük çalışma, yüksek düzeyde tavuk onkogenik virüslere maruz kalan bir insan grubunun birkaç kanser türünde ölüm riskinin arttığını kanıtlamaktadır. Diğer mesleki karsinojenik maruziyetler, örneğin ambalaj makinelerinden çıkan duman, bazı bulguların açıklanmasında önemli olabilir. Bu bulgular, bu virüslere maruz kalan genel nüfusun halk sağlığı üzerinde de etkileri olabileceğini düşündürmektedir. Şimdi, belirli kanserlerin aşırı oranlarının belirli mesleki maruziyetlere atfedilebilmesini ve aynı zamanda diğer potansiyel mesleki ve mesleki olmayan karsinojenik maruziyetlere karşı iyi bir şekilde kontrol edilmesini sağlayacak epidemiyolojik çalışmalar gerekmektedir. 2010 Elsevier B.V. Tüm hakları saklıdır.",True
5,watermelon,karpuz,True
6,domoic acid,domoik asit,True
7,Melatonin & Breast Cancer,Melatonin & Memeli Kanseri,True
8,Treadmill Desks: Stand Up For Health,"Yürüyüş Masaları: Sağlığa Kalkan Olun

## Introduction

In today's fast-paced world, maintaining a healthy lifestyle is more important than ever. One effective way to do this is by incorporating regular physical activity into your daily routine. Treadmill desks offer a unique solution to this challenge, allowing individuals to walk and work at the same time.

## Benefits of Treadmill Desks

Walking while working has numerous advantages:
- **Improved Cardiovascular Health**: Regular walking sessions on a treadmill desk can significantly enhance your heart and lung function, reducing the risk of cardiovascular diseases.
- **Weight Management**: Combining exercise with work helps burn calories and maintain a healthy weight.
- **Enhanced Mental Well-being**: Physical activity releases endorphins, which can improve mood, reduce stress, and boost overall mental health.
- **Increased Productivity**: Treadmill desks enable individuals to stay active while completing tasks, potentially leading to higher productivity levels.

## Incorporating Treadmill Desks into Your Workspace

Setting up a treadmill desk in your home or office is a straightforward process:
- **Choose the Right Model**: Select a treadmill desk that suits your height, weight, and desired features.
- **Assembly and Placement**: Follow the manufacturer's instructions for assembly and place the desk in a convenient location, ensuring enough space for walking.
- **Adjust Settings**: Personalize the speed and incline settings to match your comfort and fitness level.
- **Ergonomics**: Ensure the desk is at a suitable height for typing and walking, promoting a healthy posture.

## Conclusion

Treadmill desks represent a practical and innovative way to integrate physical activity into our sedentary lifestyles. By standing up and walking while working, individuals can reap the numerous health benefits while also increasing productivity. With the right setup and consistent use, treadmill desks can be a powerful tool for maintaining a healthy and active lifestyle.",True
9,soy,ben,True
10,"RATIONALE: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer's disease (AD). OBJECTIVE: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD. METHODS: Fifty-four Persian-speaking adults 55 years of age or older who were living in the community were eligible to participate in a 22-week, double-blind study of parallel groups of patients with AD. The main efficacy measures were the change in the Alzheimer's Disease Assessment Scale-cognitive subscale and Clinical Dementia Rating Scale-Sums of Boxes scores compared with baseline. Adverse events (AEs) were systematically recorded. Participants were randomly assigned to receive a capsule saffron 30 mg/day (15 mg twice per day) or donepezil 10 mg/day (5 mg twice per day). RESULTS: Saffron at this dose was found to be effective similar to donepezil in the treatment of mild-to-moderate AD after 22 weeks. The frequency of AEs was similar between saffron extract and donepezil groups with the exception of vomiting, which occurred significantly more frequently in the donepezil group. CONCLUSION: This phase II study provides preliminary evidence of a possible therapeutic effect of saffron extract in the treatment of patients with mild-to-moderate Alzheimer's disease. This trial is registered with the Iranian Clinical Trials Registry (IRCT138711051556N1).","RATİONEL: Alzheimer hastalığı (AD) tedavisinde Crocus sativus (saffron)ın olası etkinliği hakkında artan kanıtlar vardır.

HEDEF: Bu araştırmanın amacı, hafif ila orta derecede AD olan hastalarda C. sativus'un etkinliğini değerlendirmekti.

YÖNTEMLER: 55 yaş ve üstü, toplulukta yaşayan 54 Farsça konuşan yetişkin, 22 haftalık, çift kör, paralel gruplar halinde AD hastalarının katılımına uygun hale geldi. Ana etkin ölçümler, Alzheimer Hastalığı Değerlendirme Ölçeği-Bilişsel alt ölçekteki değişiklik ve Klinik Demans Derecelendirme Ölçeği-Kutuların Toplamı puanlarına kıyasla baz çizgisiydi. Yan etkiler (AEs) sistematik olarak kaydedildi. Katılımcılar, 30 mg/gün kapsül safran (günde iki kez 15 mg) veya 10 mg/gün donepezil (günde iki kez 5 mg) almaları için rastgele atandı.

SONUÇLAR: Bu dozda safran, 22 hafta sonra hafif ila orta derecede AD tedavisinde donepezil'e benzer olarak etkili bulundu. AEs sıklığı, safran ekstraktı ve donepezil grupları arasında benzer idi, ancak kusma, donepezil grubunda anlamlı olarak daha sık meydana geldi.

SONUÇ: Bu faz II çalışması, hafif ila orta derecede Alzheimer hastalığı olan hastalarda safran ekstraktının olası terapötik etkisine dair önsel kanıtlar sağlar. Bu deneme, İran Klinik Denemeler Kayıtları (IRCT138711051556N1) ile kayıtlıdır.",False
11,"Background Epithelial barrier function is impaired in Crohn's disease. Aim To define the underlying cellular mechanisms with special attention to tight junctions. Methods Biopsy specimens from the sigmoid colon of patients with mild to moderately active or inactive Crohn's disease were studied in Ussing chambers, and barrier function was determined by impedance analysis and conductance scanning. Tight junction structure was analysed by freeze fracture electron microscopy, and tight junction proteins were investigated immunohistochemically by confocal laser scanning microscopy and quantified in immunoblots. Epithelial apoptosis was analysed in terminal deoxynucleotidyl transferase‐mediated deoxyuridine triphosphate nick‐end labelling and 4′,6‐diamidino‐2‐phenylindole staining. Results Patients with active Crohn's disease showed an impaired intestinal barrier function as indicated by a distinct reduction in epithelial resistance. As distribution of conductivity was even, focal epithelial lesions (eg, microerosions) did not contribute to barrier dysfunction. Instead, freeze fracture electron microscopy analysis showed reduced and discontinuous tight junction strands. Occludin and the sealing tight junction proteins claudin 5 and claudin 8 were downregulated and redistributed off the tight junction, whereas the pore‐forming tight junctions protein claudin 2 was strongly upregulated, which constitute the molecular basis of tight junction changes. Other claudins were unchanged (claudins 1, 4 and 7) or not detectable in sigmoid colon (claudins 11, 12, 14, 15 and 16). Claudin 2 upregulation was less pronounced in active Crohn's disease compared with active ulcerative colitis and was inducible by tumour necrosis factor α. As a second source of impaired barrier function, epithelial apoptosis was distinctly increased in active Crohn's disease (mean (SD) 5.2 (0.5)% v 1.9 (0.2)% in control). By contrast, barrier function, tight junction proteins and apoptosis were unaffected in Crohn's disease in remission. Conclusion Upregulation of pore‐forming claudin 2 and downregulation and redistribution of sealing claudins 5 and 8 lead to altered tight junction structure and pronounced barrier dysfunction already in mild to moderately active Crohn's disease.","Arka plan Epitel bari fonksiyonu Crohn hastalığında bozulur. Amaç: Sıkı bağlantıların alttaki hücresel mekanizmalarını, özellikle sıkı bağlantıların üzerinde dikkatle tanımlamak. Yöntemler: Sigmoid kolonun hafif ila orta derecede aktif veya inaktif Crohn hastalığı olan hastalardan biyopsi örnekleri, Ussing odalarında incelendi ve bariyer fonksiyonu, direnç analizi ve iletkenlik tarama ile belirlendi. Sıkı bağlantı yapısı, donma kırılma elektron mikroskopisi ile incelendi ve sıkı bağlantı proteinleri, konfokal lazer tarama mikroskopisi ile immünohistokimyasal olarak araştırıldı ve immünoblottlarda nicelendirildi. Epitel apoptozu, terminal deoksinükleotit transferaz ile deoksiribonükleik asit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit nükleotit",False
12,"Background Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment, and when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also depend on the severity of initial depression scores. The purpose of this analysis is to establish the relation of baseline severity and antidepressant efficacy using a relevant dataset of published and unpublished clinical trials. Methods and Findings We obtained data on all clinical trials submitted to the US Food and Drug Administration (FDA) for the licensing of the four new-generation antidepressants for which full datasets were available. We then used meta-analytic techniques to assess linear and quadratic effects of initial severity on improvement scores for drug and placebo groups and on drug–placebo difference scores. Drug–placebo differences increased as a function of initial severity, rising from virtually no difference at moderate levels of initial depression to a relatively small difference for patients with very severe depression, reaching conventional criteria for clinical significance only for patients at the upper end of the very severely depressed category. Meta-regression analyses indicated that the relation of baseline severity and improvement was curvilinear in drug groups and showed a strong, negative linear component in placebo groups. Conclusions Drug–placebo differences in antidepressant efficacy increase as a function of baseline severity, but are relatively small even for severely depressed patients. The relationship between initial severity and antidepressant efficacy is attributable to decreased responsiveness to placebo among very severely depressed patients, rather than to increased responsiveness to medication. Editors' Summary Background. Everyone feels miserable occasionally. But for some people—those with depression—these sad feelings last for months or years and interfere with daily life. Depression is a serious medical illness caused by imbalances in the brain chemicals that regulate mood. It affects one in six people at some time during their life, making them feel hopeless, worthless, unmotivated, even suicidal. Doctors measure the severity of depression using the “Hamilton Rating Scale of Depression” (HRSD), a 17–21 item questionnaire. The answers to each question are given a score and a total score for the questionnaire of more than 18 indicates severe depression. Mild depression is often treated with psychotherapy or talk therapy (for example, cognitive–behavioral therapy helps people to change negative ways of thinking and behaving). For more severe depression, current treatment is usually a combination of psychotherapy and an antidepressant drug, which is hypothesized to normalize the brain chemicals that affect mood. Antidepressants include “tricyclics,” “monoamine oxidases,” and “selective serotonin reuptake inhibitors” (SSRIs). SSRIs are the newest antidepressants and include fluoxetine, venlafaxine, nefazodone, and paroxetine. Why Was This Study Done? Although the US Food and Drug Administration (FDA), the UK National Institute for Health and Clinical Excellence (NICE), and other licensing authorities have approved SSRIs for the treatment of depression, some doubts remain about their clinical efficacy. Before an antidepressant is approved for use in patients, it must undergo clinical trials that compare its ability to improve the HRSD scores of patients with that of a placebo, a dummy tablet that contains no drug. Each individual trial provides some information about the new drug's effectiveness but additional information can be gained by combining the results of all the trials in a “meta-analysis,” a statistical method for combining the results of many studies. A previously published meta-analysis of the published and unpublished trials on SSRIs submitted to the FDA during licensing has indicated that these drugs have only a marginal clinical benefit. On average, the SSRIs improved the HRSD score of patients by 1.8 points more than the placebo, whereas NICE has defined a significant clinical benefit for antidepressants as a drug–placebo difference in the improvement of the HRSD score of 3 points. However, average improvement scores may obscure beneficial effects between different groups of patient, so in the meta-analysis in this paper, the researchers investigated whether the baseline severity of depression affects antidepressant efficacy. What Did the Researchers Do and Find? The researchers obtained data on all the clinical trials submitted to the FDA for the licensing of fluoxetine, venlafaxine, nefazodone, and paroxetine. They then used meta-analytic techniques to investigate whether the initial severity of depression affected the HRSD improvement scores for the drug and placebo groups in these trials. They confirmed first that the overall effect of these new generation of antidepressants was below the recommended criteria for clinical significance. Then they showed that there was virtually no difference in the improvement scores for drug and placebo in patients with moderate depression and only a small and clinically insignificant difference among patients with very severe depression. The difference in improvement between the antidepressant and placebo reached clinical significance, however, in patients with initial HRSD scores of more than 28—that is, in the most severely depressed patients. Additional analyses indicated that the apparent clinical effectiveness of the antidepressants among these most severely depressed patients reflected a decreased responsiveness to placebo rather than an increased responsiveness to antidepressants. What Do These Findings Mean? These findings suggest that, compared with placebo, the new-generation antidepressants do not produce clinically significant improvements in depression in patients who initially have moderate or even very severe depression, but show significant effects only in the most severely depressed patients. The findings also show that the effect for these patients seems to be due to decreased responsiveness to placebo, rather than increased responsiveness to medication. Given these results, the researchers conclude that there is little reason to prescribe new-generation antidepressant medications to any but the most severely depressed patients unless alternative treatments have been ineffective. In addition, the finding that extremely depressed patients are less responsive to placebo than less severely depressed patients but have similar responses to antidepressants is a potentially important insight into how patients with depression respond to antidepressants and placebos that should be investigated further. Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050045.","Arka Plan Meta analizler, antidepresan ilaçlarının sadece aldatıcı tedaviye kıyasla sınırlı faydalarını bildirmiştir ve yayınlanmamış deneme verileri dahil edildiğinde, fayda kabul edilebilir klinik kriterlerin altında kalır. Bununla birlikte, antidepresanların etkinliği de başlangıç depresyon puanlarının şiddetine bağlı olabilir. Bu analizin amacı, ilgili bir deneme veri seti kullanarak başlangıç şiddetliği ve antidepresan etkinliği arasındaki ilişkiyi kurmaktır. Yöntem ve Bulgular ABD Gıda ve İlaç İdaresi (FDA) için lisanslama amacıyla sunulan tüm klinik denemelerden elde edilen verileri aldık. Ardından, ilaç ve aldatıcı gruplar için iyileşme puanlarına ve ilaç-aldatıcı fark puanlarına lineer ve kare etkilerini değerlendirmek için meta analitik teknikler kullandık. İlaç-aldatıcı farkları, başlangıç şiddetliği arttıkça artmaktadır, ancak hafif depresyonda olan hastalarda bile nispeten küçüktür. Başlangıç şiddetliği ve antidepresan etkinliği arasındaki ilişki, çok şiddetli depresyonda olan hastalarda aldatıcıya karşı azalan duyarlılığa, ilaçlara karşı artan duyarlılığa değil, daha çok bağlıdır. Düzenleyiciler Özet Antidepresanlar, beyin kimyasallarını düzenleyerek ruh halini etkileyen bir tıbbi durum olan depresyonun tedavisinde kullanılır. Antidepresanlar, ""tricyclikler"", ""monoamin oksidaz inhibitörleri"" ve ""selekif serotonin geri alım inhibitörleri"" (SSRI'lar) içerir. SSRI'lar, en yeni antidepresanlardır ve fluoksetin, venlafaksin, nefazodon ve paroksetin içerir. Neden Bu Çalışma Yapıldı? ABD FDA, Birleşik Krallık Ulusal Sağlık ve Klinik Mükemmellik Enstitüsü (NICE) ve diğer lisans yetkilileri, SSRI'ların depresyon tedavisinde kullanılmasına onay vermiş olsa da, klinik etkinliği konusunda bazı şüpheler devam etmektedir. Bir antidepresanın hastalarda ruh halini iyileştirme yeteneğini değerlendirmek için, ilaç ve aldatıcı tabletler içeren klinik denemeler gerçekleştirilmelidir. Her bireysel deneme, yeni ilacın etkinliği hakkında bazı bilgi sağlar, ancak ek bilgi, birçok çalışmanın sonuçlarını birleştiren bir ""meta analiz"" ile elde edilebilir. Daha önce yayınlanan bir meta analiz, FDA'ya sunulan yayınlanan ve yayınlanmamış SSRI denemeleri",False
13,"Background There is overwhelming evidence that behavioural factors influence health, but their combined impact on the general population is less well documented. We aimed to quantify the potential combined impact of four health behaviours on mortality in men and women living in the general community. Methods and Findings We examined the prospective relationship between lifestyle and mortality in a prospective population study of 20,244 men and women aged 45–79 y with no known cardiovascular disease or cancer at baseline survey in 1993–1997, living in the general community in the United Kingdom, and followed up to 2006. Participants scored one point for each health behaviour: current non-smoking, not physically inactive, moderate alcohol intake (1–14 units a week) and plasma vitamin C >50 mmol/l indicating fruit and vegetable intake of at least five servings a day, for a total score ranging from zero to four. After an average 11 y follow-up, the age-, sex-, body mass–, and social class–adjusted relative risks (95% confidence intervals) for all-cause mortality(1,987 deaths) for men and women who had three, two, one, and zero compared to four health behaviours were respectively, 1.39 (1.21–1.60), 1.95 (1.70–-2.25), 2.52 (2.13–3.00), and 4.04 (2.95–5.54) p < 0.001 trend. The relationships were consistent in subgroups stratified by sex, age, body mass index, and social class, and after excluding deaths within 2 y. The trends were strongest for cardiovascular causes. The mortality risk for those with four compared to zero health behaviours was equivalent to being 14 y younger in chronological age. Conclusions Four health behaviours combined predict a 4-fold difference in total mortality in men and women, with an estimated impact equivalent to 14 y in chronological age.  Editors' Summary Background. Every day, or so it seems, new research shows that some aspect of lifestyle—physical activity, diet, alcohol consumption, and so on—affects health and longevity. For the person in the street, all this information is confusing. What is a healthy diet, for example? Although there are some common themes such as the benefit of eating plenty of fruit and vegetables, the details often differ between studies. And exactly how much physical activity is needed to improve health? Is a gentle daily walk sufficient or simply a stepping stone to doing enough exercise to make a real difference? The situation with alcohol consumption is equally confusing. Small amounts of alcohol apparently improve health but large amounts are harmful. As a result, it can be hard for public-health officials to find effective ways to encourage the behavioral changes that the scientific evidence suggests might influence the health of populations. Why Was This Study Done? There is another factor that is hindering official attempts to provide healthy lifestyle advice to the public. Although there is overwhelming evidence that individual behavioral factors influence health, there is very little information about their combined impact. If the combination of several small differences in lifestyle could be shown to have a marked effect on the health of populations, it might be easier to persuade people to make behavioral changes to improve their health, particularly if those changes were simple and relatively easy to achieve. In this study, which forms part of the European Prospective Investigation into Cancer and Nutrition (EPIC), the researchers have examined the relationship between lifestyle and the risk of dying using a health behavior score based on four simply defined behaviors—smoking, physical activity, alcohol drinking, and fruit and vegetable intake. What Did the Researchers Do and Find? Between 1993 and 1997, about 20,000 men and women aged 45–79 living in Norfolk UK, none of whom had cancer or cardiovascular disease (heart or circulation problems), completed a health and lifestyle questionnaire, had a health examination, and had their blood vitamin C level measured as part of the EPIC-Norfolk study. A health behavior score of between 0 and 4 was calculated for each participant by giving one point for each of the following healthy behaviors: current non-smoking, not physically inactive (physical inactivity was defined as having a sedentary job and doing no recreational exercise), moderate alcohol intake (1–14 units a week; a unit of alcohol is half a pint of beer, a glass of wine, or a shot of spirit), and a blood vitamin C level consistent with a fruit and vegetable intake of at least five servings a day. Deaths among the participants were then recorded until 2006. After allowing for other factors that might have affected their likelihood of dying (for example, age), people with a health behavior score of 0 were four times as likely to have died (in particular, from cardiovascular disease) than those with a score of 4. People with a score of 2 were twice as likely to have died. What Do These Findings Mean? These findings indicate that the combination of four simply defined health behaviors predicts a 4-fold difference in the risk of dying over an average period of 11 years for middle-aged and older people. They also show that the risk of death (particularly from cardiovascular disease) decreases as the number of positive health behaviors increase. Finally, they can be used to calculate that a person with a health score of 0 has the same risk of dying as a person with a health score of 4 who is 14 years older. These findings need to be confirmed in other populations and extended to an analysis of how these combined health behaviors affect the quality of life as well as the risk of death. Nevertheless, they strongly suggest that modest and achievable lifestyle changes could have a marked effect on the health of populations. Armed with this information, public-health officials should now be in a better position to encourage behavior changes likely to improve the health of middle-aged and older people. Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050012.","Arka Plan: Davranışsal faktörlerin sağlığı etkilediğine dair kesin kanıtlar var, ancak genel nüfusta bunların birleştirilmiş etkisinin daha az belgelendirildiği görülmektedir. Dört sağlık davranışının potansiyel birleştirilmiş etkisini, kalp ve damar hastalıkları veya kanser gibi bilinen kardiyovasküler hastalık veya kanser olmaksızın 1993-1997 yılları arasında Birleşik Krallık'ta genel toplulukta yaşayan 45-79 yaş arası 20.244 erkek ve kadın üzerinde inceleyerek ölüm oranlarını ölçmeyi amaçladık. Yöntemler ve Bulgular: EPIC-Norfolk çalışmasının bir parçası olarak, 1993-1997 yılları arasında Norfolk, Birleşik Krallık'ta 45-79 yaş arası 20.244 erkek ve kadın, bilinen kardiyovasküler hastalık veya kanser olmaksızın, bir sağlık ve yaşam tarzı anketini doldurmuş, sağlık muayenesi geçirmiş ve kan vitamin C seviyeleri ölçülmüşlerdir. Katılımcılara, şu sağlıklı davranışlar için her biri bir puan verilerek 0 ile 4 arasında bir sağlık davranış puanı hesaplanmıştır: mevcut sigara içmeme, fiziksel hareketsizlik (sedenteryan bir işte çalışmak ve herhangi bir rekreasyonel egzersiz yapmamak), 1-14 birim haftalık alkol tüketimi (birim, yarım bira, bir kadeh şarap veya bir şot ruh olarak hesaplanır) ve en az beş porsiyon günde meyve ve sebze tüketimine işaret eden 50 mmol/l'den fazla kan vitamin C seviyesi. Katılımcıların takip süresi ortalama 11 yıldır. Yaş, cinsiyet, vücut kitle endeksi ve sosyal sınıf ayarlamaları yapılmış yaşa bağlı tüm nedenlerden ölüm (1.987 ölüm) riskleri için 0, 1, 2 ve 3 sağlıklı davranışa sahip erkek ve kadınların sırasıyla 1.39 (1.21-1.60), 1.95 (1.70-2.25), 2.52 (2.13-3.00) ve 4.04 (2.95-5.54) p < 0.001 eğilimi gözlemlenmiştir. İlişkiler, cinsiyet, yaş, vücut kitle endeksi ve sosyal sınıf alt",False
14,"IMPORTANCE: Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy. OBJECTIVES: To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries. DESIGN: We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries. Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age. Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health. Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs. Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs. Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages. RESULTS: US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years. The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury. Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls. The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders. As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs. The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use. Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th. CONCLUSIONS AND RELEVANCE: From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable. However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations.","ÖNEMLİLİK: Amerika Birleşik Devletleri'nde (ABD) büyük sağlık sorunlarını ve zaman içinde nasıl değiştiğini anlamak, ulusal sağlık politikasını bilgilendirmek için kritik öneme sahiptir. HEDEFLER: 1990 ile 2010 yılları arasında ABD'de hastalıklar, yaralanmalar ve önde gelen risk faktörlerinin yükünü ölçmek ve bu ölçümleri OECD (Ekonomik İşbirliği ve Kalkınma Örgütü) ülkelerindeki 34 ülkenin ölçümleriyle karşılaştırmak. TASARIM: Global Yük 2010 Çalışması için geliştirilen 291 hastalık ve yaralanma, 1160'ın üzerinde bu hastalıklar ve yaralanmaların sekansları ve 67 risk faktörü veya risk faktörlerinin kümeleri için 1990 ile 2010 yılları arasında 187 ülke için sistematik epidemiyolojik analiz kullandık. Ömür kaybı nedeniyle erken ölüm (YLL) sayıları, her yaşta ölüm sayısını referans ömür beklentisiyle çarparak hesaplandı. Engelli yaşam yılları (YLD), her sekans için yaygınlık (sistematik incelemeler temelinde) ve sakatlık ağırlığı (toplum temelli anketler temelinde) çarparak hesaplandı; bu çalışmada sakatlık, herhangi bir kısa veya uzun süreli sağlığın kaybını ifade eder. Engelli yaşam yıllarına (DALY) YLD ve YLL'lerin toplamı eklendi. Risk faktörlerine bağlı ölümler ve DALY'ler, risk-sonuç çiftleri için maruz kalma verileri ve göreli riskler üzerine sistematik incelemeler ve meta-analizlere dayanıyordu. Sağlıklı yaşam beklentisi (HALE), genel nüfus sağlığını özetlemek için, hem yaşam süresini hem de farklı yaşlarda deneyimlenen sağlıksızlık seviyelerini hesaba katarak kullanıldı. SONUÇLAR: Hem erkek hem de kadınlarda birleştirilmiş yaşam beklentisi, 1990'da 75.2 yıldan 2010'da 78.2 yıla yükseldi; aynı dönemde HALE, 65.8 yıldan 68.1 yıla yükseldi. 2010'da en fazla YLL'ye neden olan hastalıklar ve yaralanmalar, izemik kalp hastalığı, akciğer kanseri",False
15,Mioscene,"Miyosin

# English Text:
The mioscene is a dynamic, three-dimensional (3D) model of a cell's internal environment, representing the spatial organization of macromolecules, organelles, and other cellular components.

# Translated Text:
Miyosin, bir hücrenin iç ortamının dinamik, üç boyutlu (3D) bir modelidir, makromoleküllerin, organellerin ve diğer hücresel bileşenlerin mekansal organizasyonunu temsil eder.",False
